LumiraDx Investor Presentation Deck

Instruments shipped (1) Strategic Partner Key Products(2) lumiraDx™ Customer Focused Growth Strategy Near-Term Opportunities Physician Office / Pharmacy ♥CVS pharmacy 8,500+ US and Global Health Systems Boots COVID Antigen / Ultra √ Flu A/B + COVID √ RSV + COVID-19 √ Strep A Molecular CRP √ HbA1c √ INR √ Na/K Lipids D-Dimer NT-proBNP Acute / Emergency Care 5,400+ NHS HS Troponin BNP D-Dimer √ NT-proBNP COVID Antigen / Ultra √ Flu A/B + COVID √ RSV + COVID-19 √ Procalcitonin Global Health Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide 5, 100+ BILL MELINDA GATES foundation TB Molecular HIV Viral Load COVID Antigen / Ultra CRP √ D-Dimer √ INR √ HbA1c √ (1) Total instrumentshipments are 25,000+ with 6,000+ estimated for use in COVID screening applications with future testing needs to be determined (2) Tests critical to launch in customer segmentare bolded; tests with regulatoryauthorization in initial market, and currently commercially available or planned to be available in H2 2022, are checked 45

View entire presentation